New shot aims to tame severe asthma attacks
NCT ID NCT07456033
Summary
This study is testing whether adding a new injectable medication called depemokimab to standard asthma care can help people with a specific type of asthma (Type 2) who are prone to serious flare-ups. About 456 adults and teenagers will receive either the new medication or a placebo (dummy shot) alongside their usual treatments for up to 3 years. Researchers will measure if the new treatment reduces the number of asthma attacks, helps people achieve remission, and slows the decline in lung function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.